8:56 PM
 | 
Jan 18, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Syntimmune reports Phase Ia data for autoimmune disease candidate

Syntimmune Inc. (Waltham, Mass.) reported data from a Phase Ia trial in 31 healthy volunteers showing that single ascending doses of IgG-mediated autoimmune disease candidate IV SYNT001 were well tolerated with no serious adverse events reported. The company...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >